Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
暂无分享，去创建一个
E. Perez | H. Rugo | J. Ahn | S. Im | J. O’Shaughnessy | D. Potter | C. Twelves | A. Awada | V. Diéras | D. Yardley | J. Cortés | M. Tagliaferri | L. Schwartzberg | P. Gómez-Pardo | A. Hannah | U. Hoch | A. Moreno-Aspitia | A. Mailliez | Carol Zhao